- Home
- GH
as of 03-20-2026 2:39pm EST
$84.65
$4.43
-4.97%
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 13.3B | IPO Year: | 2018 |
| Target Price: | $117.80 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.32 | EPS Growth: | 6.74 |
| 52 Week Low/High: | $36.36 - $120.74 | Next Earning Date: | 04-29-2026 |
| Revenue: | $982,021,000 | Revenue Growth: | 32.88% |
| Revenue Growth (this year): | 33.4% | Revenue Growth (next year): | 28.55% |
| P/E Ratio: | -26.95 | Index: | N/A |
| Free Cash Flow: | -233066000.0 | FCF Growth: | N/A |
AI-Powered GH Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 19 hours ago
AI Recommendation
hold
Model Accuracy: 68.94%
68.94%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Guardant Health Inc. (GH)
Tariq Musa
Sell
Director
GH Mar 18, 2026
Avg Cost/Share
$88.09
Shares
348
Total Value
$30,655.32
Owned After
8,394
SEC Form 4
Bell Michael Brian
Sell
Chief Financial Officer
GH Mar 16, 2026
Avg Cost/Share
$87.04
Shares
3,000
Total Value
$261,111.00
Owned After
43,601
SEC Form 4
Hidalgo Medina Manuel
Sell
Director
GH Mar 6, 2026
Avg Cost/Share
$91.45
Shares
1,300
Total Value
$118,996.53
Owned After
1,193
Kalia Kumud
Sell
Chief Information Officer
GH Mar 4, 2026
Avg Cost/Share
$95.42
Shares
40,000
Total Value
$3,812,660.54
Owned After
50,663
Monroe Terilyn J.
Sell
Chief People Officer
GH Jan 21, 2026
Avg Cost/Share
$113.84
Shares
8,571
Total Value
$977,901.82
Owned After
20,990
Monroe Terilyn J.
Sell
Chief People Officer
GH Jan 7, 2026
Avg Cost/Share
$112.60
Shares
10,031
Total Value
$1,124,279.50
Owned After
20,990
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Tariq Musa | GH | Director | Mar 18, 2026 | Sell | $88.09 | 348 | $30,655.32 | 8,394 | |
| Bell Michael Brian | GH | Chief Financial Officer | Mar 16, 2026 | Sell | $87.04 | 3,000 | $261,111.00 | 43,601 | |
| Hidalgo Medina Manuel | GH | Director | Mar 6, 2026 | Sell | $91.45 | 1,300 | $118,996.53 | 1,193 | |
| Kalia Kumud | GH | Chief Information Officer | Mar 4, 2026 | Sell | $95.42 | 40,000 | $3,812,660.54 | 50,663 | |
| Monroe Terilyn J. | GH | Chief People Officer | Jan 21, 2026 | Sell | $113.84 | 8,571 | $977,901.82 | 20,990 | |
| Monroe Terilyn J. | GH | Chief People Officer | Jan 7, 2026 | Sell | $112.60 | 10,031 | $1,124,279.50 | 20,990 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 19, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 19, 2026 · 100% conf.
AI Prediction SELL
1D
-5.84%
$100.17
Act: -3.08%
5D
-11.20%
$94.47
Act: -7.91%
20D
-3.97%
$102.16
Act: -15.91%
Price: $106.38 Prob +5D: 0% AUC: 1.000
0001576280-26-000012
gh-202602190001576280false00015762802026-02-192026-02-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 19, 2026
GUARDANT HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-3868345-4139254
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
3100 Hanover Street Palo Alto, California 94304 (Address of principal executive offices) (Zip Code) 855-698-8887 (Registrant’s telephone number, include area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.00001 par value per share GH The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 19, 2026, Guardant Health, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.Description 99.1Press release of Guardant Health, Inc., dated February 19, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GUARDANT HEALTH, INC.
Date:February 19, 2026By:/s/ Michael Bell
Michael Bell
Chief Financial Officer
(Principal Accounting Officer and Principal Financial Officer)
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
AI Prediction SELL
1D
-5.84%
$100.17
Act: -3.08%
5D
-11.20%
$94.47
Act: -7.91%
20D
-3.97%
$102.16
Act: -15.91%
Price: $106.38 Prob +5D: 0% AUC: 1.000
0001576280-26-000004
gh-202601110001576280false00015762802026-01-112026-01-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2026
GUARDANT HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-3868345-4139254
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
3100 Hanover Street Palo Alto, California 94304 (Address of principal executive offices) (Zip Code) 855-698-8887 (Registrant’s telephone number, include area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.00001 par value per share GH The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Conditions.
On January 11, 2026, Guardant Health, Inc. (the “Company”) announced certain preliminary unaudited financial information for the quarter and full year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 7.01. Regulation FD Disclosure.
The Company will post the presentation that it will present at the 2026 J.P. Morgan Healthcare Conference on January 12, 2026 to the Company’s website, www.guardanthealth.com, on the “Events & Presentations” page under the “Investors” tab.
The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.Description 99.1Press Release of Guardant Health, Inc., dated January 11, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GUARDANT HEALTH, INC.
Date:January 12, 2026By:/s/ Michael Bell Michael Bell
Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)
2025 Q3 Q3 2025 Earnings
8-K Oct 29, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 29, 2025
0001576280-25-000276
gh-202510290001576280false00015762802025-10-292025-10-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 29, 2025
GUARDANT HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-3868345-4139254
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
3100 Hanover Street Palo Alto, California 94304 (Address of principal executive offices) (Zip Code) 855-698-8887 (Registrant’s telephone number, include area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.00001 par value per share GH The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On October 29, 2025, Guardant Health, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.Description 99.1Press release of Guardant Health, Inc., dated October 29, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
GUARDANT HEALTH, INC.
Date:October 29, 2025By:/s/ Michael Bell
Michael Bell
Chief Financial Officer
(Principal Accounting Officer and Principal Financial Officer)
Latest Guardant Health Inc. News
GH Breaking Stock News: Dive into GH Ticker-Specific Updates for Smart Investing
TMX Newsfile
Gamehost to Correct Administrative Expense Allocation in Financial Statements; No Impact on Operations or Cash Flow
📉
AI Sentiment
Negative
3/10
MT Newswires
Guardant Health to Launch Multicancer Detection Test in Asia With Manulife Financial
📊
AI Sentiment
Positive
7/10
Compare GH vs Leading Stocks
See how GH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GH Guardant Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.